01
Cash & equivalents increased 28.7%
Cash & equivalents changed +28.7% from the comparable as-filed period.
$14.7M→$18.9MComparable → current
· Pharmaceutical Preparations
RESEARCH SNAPSHOTCorvus Pharmaceuticals, Inc.'s latest supported as-filed period reports net income of -$18.0M, 124.5% below the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +28.7% from the comparable as-filed period.
Net income changed -124.5% from the comparable as-filed period.
Operating income changed -88.1% from the comparable as-filed period.
Research & development changed +102.8% from the comparable as-filed period.
Each point keeps the date investors could first observe it and its accession.
CRVS · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001104659-26-091975SEC ↗8-KAug 6, 2026Period Aug 6, 20260001171843-26-005317SEC ↗8-KJul 22, 2026Period Jul 21, 20260001104659-26-085790SEC ↗4Jun 15, 2026Period Jun 11, 20260001610717-26-000223SEC ↗4Jun 15, 2026Period Jun 11, 20260001610717-26-000222SEC ↗4Jun 15, 2026Period Jun 11, 20260001610717-26-000221SEC ↗4Jun 15, 2026Period Jun 11, 20260001610717-26-000220SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Stock-based compensation changed +107.7% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001610717-26-000219